Related Experiment Video
Updated: Jun 1, 2026
07:32
Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019
Identification of a LNCaP-specific binding peptide using phage display.
Bin Qin1, Wanyi Tai, Ravi S Shukla
1Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte Street, Kansas City, Missouri, 64108, USA.
Pharmaceutical Research
|May 26, 2011
Summary
Researchers identified a specific peptide targeting LNCaP cells for potential drug delivery. This peptide showed promise in delivering therapeutic agents and inducing cell death in targeted cancer cells.
Area of Science:
- Biotechnology
- Molecular Biology
- Cancer Research
Background:
- Prostate cancer remains a significant health concern, necessitating novel therapeutic strategies.
- Targeted drug delivery systems aim to improve treatment efficacy and reduce side effects.
- Phage display technology offers a powerful tool for identifying specific molecular ligands.
Purpose of the Study:
- To discover a peptide with high specificity for LNCaP prostate cancer cells.
- To assess the potential of this peptide in targeted drug delivery applications.
- To evaluate the peptide's ability to induce apoptosis and deliver nucleic acids.
Main Methods:
- Phage display library screening was employed to isolate LNCaP-specific phages.
- Cell-based assays, including ELISA and immunostaining, were used to confirm binding specificity.
- Synthesized peptides were conjugated to therapeutic payloads (proapoptotic peptide, siRNA) for functional evaluation.
Main Results:
- A phage clone displaying a high-affinity peptide (KYL) specific to LNCaP cells was identified.
- The KYL peptide demonstrated selective binding to LNCaP cells over other cell lines.
- A fusion peptide induced LNCaP cell death, and a KYL-protamine conjugate successfully delivered siRNA to LNCaP cells.
Conclusions:
- A novel LNCaP-specific peptide was successfully identified using phage display.
- The identified peptide holds significant potential for targeted drug delivery in prostate cancer therapy.
- This peptide can be utilized for targeted delivery of both cytotoxic agents and gene-silencing molecules.
